Scholarlink

<p>Landiolol enables rapid and titratable heart rate control in perioperative and critically ill patients. In supraventricular tachyarrhythmias and perioperative settings, available studies suggest effective rate control and acceptable hemodynamic tolerance. In sepsis and septic shock with persistent tachycardia, landiolol consistently lowers heart rate without increasing vasopressor requirements; however, randomized evidence does not demonstrate consistent benefits on major clinical outcomes, and current guidelines do not support its routine use. Emerging data on decatecholaminization strategies indicate that combining landiolol with non-adrenergic vasopressors may attenuate catecholamine-related toxicity and improve hemodynamic profiles. Experimental and perioperative studies also suggest potential anti-inflammatory effects through modulation of cytokine release. Overall, current evidence supports landiolol as a potentially useful option for acute heart rate control and selected cases of septic tachycardia. Nevertheless, given the heterogeneity of critically ill populations and the absence of clear outcome benefits in large randomized trials, its use should remain individualized and guided by careful hemodynamic monitoring, with particular attention to appropriate patient selection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Landiolol in perioperative and critical care: evidence, patient selection, and practical titration for targeted heart rate control: a narrative review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Cesare Biuzzi,
  • Giulio Carinci,
  • Lorenzo Sorelli,
  • Benedetta Bidi,
  • Chiara Albizzi,
  • Daniele Marianello,
  • Filippo Annoni,
  • Federico Franchi,
  • Gianluca Paternoster,
  • Fabio Silvio Taccone,
  • Sabino Scolletta

摘要

Landiolol enables rapid and titratable heart rate control in perioperative and critically ill patients. In supraventricular tachyarrhythmias and perioperative settings, available studies suggest effective rate control and acceptable hemodynamic tolerance. In sepsis and septic shock with persistent tachycardia, landiolol consistently lowers heart rate without increasing vasopressor requirements; however, randomized evidence does not demonstrate consistent benefits on major clinical outcomes, and current guidelines do not support its routine use. Emerging data on decatecholaminization strategies indicate that combining landiolol with non-adrenergic vasopressors may attenuate catecholamine-related toxicity and improve hemodynamic profiles. Experimental and perioperative studies also suggest potential anti-inflammatory effects through modulation of cytokine release. Overall, current evidence supports landiolol as a potentially useful option for acute heart rate control and selected cases of septic tachycardia. Nevertheless, given the heterogeneity of critically ill populations and the absence of clear outcome benefits in large randomized trials, its use should remain individualized and guided by careful hemodynamic monitoring, with particular attention to appropriate patient selection.